Galactomannan and Polymerase Chain Reaction-Based Screening for Invasive Aspergillosis among High-Risk Hematology Patients: A Diagnostic Meta-analysis

Clinical Infectious Diseases

Volumn 61, Issue 8, 2015, Pages 1263-1272

  Arvanitis, Marios ^a,b,c   Anagnostou, Theodora ^a,b   Mylonakis, Eleftherios ^a,b  

^a RHODE ISLAND HOSPITAL   (United States)

^b BROWN UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Aspergillus; Diagnosis; Fungal infection; Galactomannan; PCR

Indexed keywords

GALACTOMANNAN; FUNGAL DNA; MANNAN;

ARTICLE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INVASIVE ASPERGILLOSIS; META ANALYSIS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; ASPERGILLOSIS; ASPERGILLUS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETICS; ISOLATION AND PURIFICATION; MASS SCREENING; MICROBIOLOGY; PROCEDURES; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ASPERGILLOSIS; ASPERGILLUS; DNA, FUNGAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; MANNANS; MASS SCREENING; POLYMERASE CHAIN REACTION; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84943270127     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ555     Document Type: Article

References (42)

1. Ramos ER, Jiang Y, Hachem R, Kassis C, Kontoyiannis DP, Raad I. Outcome analysis of invasive aspergillosis in hematologic malignancy and hematopoietic stem cell transplant patients: the role of novel antimold azoles. Oncologist 2011; 16:1049-60.
2. Karthaus M. Prophylaxis and treatment of invasive aspergillosis with voriconazole, posaconazole and caspofungin: review of the literature. Eur J Med Res 2011; 16:145-52.
3. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev 2014; 27:490-526.
4. Arvanitis M, Mylonakis E. Diagnosis of invasive aspergillosis: recent developments and ongoing challenges. Eur J Clin Invest 2015; 45:646-52.
5. De Pauw B,Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813-21.
6. Arvanitis M, Ziakas PD, Zacharioudakis IM, Zervou FN, Caliendo AM, Mylonakis E. PCR in diagnosis of invasive aspergillosis: a meta-analysis of diagnostic performance. J Clin Microbiol 2014; 52:3731-42.
7. Morrissey CO, Chen SC, Sorrell TC, et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013; 13:519-28.
8. Aguado JM, Vazquez L, Fernandez-Ruiz M, et al. Serum galactomannan vs a combination of galactomannan and PCR-based Aspergillus DNA detection for early therapy of invasive aspergillosis in high-risk hematological patients: a randomized controlled trial. Clin Infect Dis 2015; 60:405-14.
9. Barnes RA, Stocking K, Bowden S, Poynton MH, White PL. Prevention and diagnosis of invasive fungal disease in high-risk patients within an integrative care pathway. J Infect 2013; 67:206-14.
10. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339:b2535.
11. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7-14.
12. Leeflang MM, Debets-Ossenkopp YJ, Visser CE, et al. Galactomannan detection for invasive aspergillosis in immunocompromized patients. Cochrane Database Syst Rev 2008; CD007394.
13. Borlenghi E, Cattaneo C, Capucci MA, et al. Usefulness of the MSG/IFICG/EORTC diagnostic criteria of invasive pulmonary aspergillosis in the clinical management of patients with acute leukaemia developing pulmonary infiltrates. Ann Hematol 2007; 86:205-10.
14. Whiting PF, Rutjes AW, Westwood ME, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155:529-36.
15. Reitsma JB, Glas AS, Rutjes AW, Scholten RJ, Bossuyt PM, Zwinderman AH. Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. J Clin Epidemiol 2005; 58:982-90.
16. Harbord RM, Whiting P, Sterne JA, et al. An empirical comparison of methods for meta-analysis of diagnostic accuracy showed hierarchical models are necessary. J Clin Epidemiol 2008; 61:1095-103.
17. Denning DW. Invasive aspergillosis. Clin Infect Dis 1998; 26:781-803; quiz 804-5.
18. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358-66.
19. Deeks JJ, Macaskill P, Irwig L. The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. J Clin Epidemiol 2005; 58:882-93.
20. Dinnes J, Deeks J, Kirby J, Roderick P. A methodological review of how heterogeneity has been examined in systematic reviews of diagnostic test accuracy. Health Technol Assess 2005; 9:1-113, iii.
21. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: data-analytic approaches and some additional considerations. Stat Med 1993; 12:1293-316.
22. Takwoingi Y. Meta-analysis of test accuracy studies in Stata: a bivariate model approach. Version 1.0. Available at: http://srdta.cochrane.org/software-development. Accessed 10 October 2014.
23. Costa C, Costa JM, Desterke C, Botterel F, Cordonnier C, Bretagne S. Real-time PCR coupled with automated DNA extraction and detection of galactomannan antigen in serum by enzyme-linked immunosorbent assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2002; 40:2224-7.
24. Scotter JM, Campbell P, Anderson TP, Murdoch DR, Chambers ST, Patton WN. Comparison of PCR-ELISA and galactomannan detection for the diagnosis of invasive aspergillosis. Pathology 2005; 37:246-53.
25. Florent M, Katsahian S, Vekhoff A, et al. Prospective evaluation of a polymerase chain reaction-ELISA targeted to Aspergillus fumigatus and Aspergillus flavus for the early diagnosis of invasive aspergillosis in patients with hematological malignancies. J Infect Dis 2006; 193:741-7.
26. Suarez F, Lortholary O, Buland S, et al. Detection of circulating Aspergillus fumigatus DNA by real-time PCR assay of large serum volumes improves early diagnosis of invasive aspergillosis in high-risk adult patients under hematologic surveillance. J Clin Microbiol 2008; 46:3772-7.
27. Cesaro S, Stenghele C, Calore E, et al. Assessment of the lightcycler PCR assay for diagnosis of invasive aspergillosis in paediatric patients with onco-haematological diseases. Mycoses 2008; 51:497-504.
28. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C, et al. Value of serial quantification of fungal DNA by a real-time PCR-based technique for early diagnosis of invasive aspergillosis in patients with febrile neutropenia. J Clin Microbiol 2009; 47:379-84.
29. Springer J, Loeffler J, Heinz W, et al. Pathogen-specific DNA enrichment does not increase sensitivity of PCR for diagnosis of invasive aspergillosis in neutropenic patients. J Clin Microbiol 2011; 49: 1267-73.
30. Springer J, Morton CO, Perry M, et al. Multicenter comparison of serum and whole-blood specimens for detection of Aspergillus DNA in high-risk hematological patients. J Clin Microbiol 2013; 51:1445-50.
31. Rogers TR, Morton CO, Springer J, et al. Combined real-time PCR and galactomannan surveillance improves diagnosis of invasive aspergillosis in high risk patients with haematological malignancies. Br J Haematol 2013; 161:517-24.
32. White PL, Parr C, Thornton C, Barnes RA. Evaluation of real-time PCR, galactomannan enzyme-linked immunosorbent assay (ELISA), and a novel lateral-flow device for diagnosis of invasive aspergillosis. J Clin Microbiol 2013; 51:1510-6.
33. da Silva TV, Carneiro LC, Ramos Fdos S, et al. PCR as a screening test for invasive aspergillosis in haematological patients: a pilot study. Mycopathologia 2014; 177:111-4.
34. Aslan M, Oz Y, Aksit F, Akay OM. Potential of polymerase chain reaction and galactomannan for the diagnosis of invasive aspergillosis in patients with febrile neutropenia. Mycoses 2015; 58:343-9.
35. White PL, Bretagne S, Klingspor L, et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010; 48:1231-40.
36. White PL, Mengoli C, Bretagne S, et al. Evaluation of Aspergillus PCR protocols for testing serum specimens. J Clin Microbiol 2011; 49:3842-8.
37. Mennink-Kersten MA, Ruegebrink D, Wasei N, Melchers WJ, Verweij PE. In vitro release by Aspergillus fumigatus of galactofuranose antigens, 1,3-beta-D-glucan, and DNA, surrogate markers used for diagnosis of invasive aspergillosis. J Clin Microbiol 2006; 44:1711-8.
38. Morton CO, Loeffler J, De Luca A, et al. Dynamics of extracellular release of Aspergillus fumigatus DNA and galactomannan during growth in blood and serum. J Med Microbiol 2010; 59:408-13.
39. Mengoli C, Cruciani M, Barnes RA, Loeffler J, Donnelly JP. Use of PCR for diagnosis of invasive aspergillosis: systematic review and metaanalysis. Lancet Infect Dis 2009; 9:89-96.
40. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42:1417-27.
41. Duarte RF, Sanchez-Ortega I, Cuesta I, et al. Serum galactomannanbased early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis 2014; 59:1696-702.
42. Marr KA, Laverdiere M, Gugel A, LeisenringW. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 2005; 40:1762-9.